Vasorelaxant actions of enoximone, dobutamine, and the combination on human arterial coronary bypass grafts

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 5, 1999, Pages 741-748

  Cracowski, Jean Luc ^a   Stanke Labesque, Françoise ^a   Chavanon, Olivier ^b   Blin, Dominique ^b   Mallion, Jean Michel ^b   Bessard, Germain ^a   Devillier, Philippe ^a  

^a UNIV GRENOBLE ALPES   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

Dobutamine; Enoximone; Gastroepiploic artery; Internal mammary artery; Phosphodiesterase inhibitor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DOBUTAMINE; ENOXIMONE; NITROPRUSSIDE SODIUM; NORADRENALIN; NORMAPUR; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHLORIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG POTENTIATION; GASTROEPIPLOIC ARTERY; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; PRIORITY JOURNAL;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; DOBUTAMINE; DRUG SYNERGISM; ENOXIMONE; HUMANS; MAMMARY ARTERIES; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; POTASSIUM CHLORIDE; STOMACH; VASOCONSTRICTOR AGENTS; VASOMOTOR SYSTEM;

EID: 0032738771     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199911000-00017     Document Type: Article

References (48)

1. Vernon MW, Heel RC, Brodgen RN. Enoximone: a review of its pharmacological properties and therapeutic potential. Drugs 1991; 42:997-1017.
2. Thuillez C, Richard C, Teboul JL, et al. Arterial hemodynamics and cardiac effects of enoximone, dobutamine and their combination in severe heart failure. Am Heart J 1993;125:799-808.
3. Likoff MJ. Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 1986;57:1328-34.
4. Installé E, Gonzales M, Jacquemart J, et al. Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine and nitroprusside in severe congestive heart failure. Am J Cardiol 1987; 60:46C-52C.
5. Crawford MH. Intravenous use of enoximone. Am J Cardiol 1987; 60:42C-5C.
6. Innes PA, Frazer RS, Booker PD, et al. Comparison of the hemodynamic effects of dobutamine with enoximone after open heart surgery in small children. Br J Anaesth 1994;72:77-81.
7. Birnbaum DE, Preuner JG, Gieseke R, Trenk D, Jaehnchen E. Enoximone versus dopamine in patients being weaned from cardiopulmonary bypass. Cardiology 1990;77(suppl 3):34-41.
8. Hachenberg T, Möllholff T, Holst D, Hammel D, Brüssel T. Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. J Cardiothorac Vasc Anesth 1997;11:453-7.
9. Hall IP. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Clin Pharmacol 1993;35:1-7.
10. Salmenperä M, Levy JH. The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery. Anesth Analg 1996;82:954-7.
11. Cracowski JL, Chavanon O, Durand M, et al. Effect of low-dose positive inotropic drugs on human internal mammary flow. Ann Thorac Surg 1997;64:1742-6.
12. Dinardo JA, Bert A, Schwartz MJ, Johnson RG, Thurer RL, Weintraub RM. Effects of vasoactive drugs on flows through left internal mammary artery and saphenous vein grafts in man. J Thorac Cardiovasc Surg 1991;102:730-5.
13. Izzat MB, West RR, Ragoonanan C, Angelini GD. Effect of systemic vasodilators on internal mammary artery flow. J Thorac Cardiovasc Surg 1994;108:82-5.
14. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal thoracic artery grafts: effects on survival over a 15-year period. N Engl J Med 1996;334:216-9.
15. Grondin CM, Campeau L, Lesperance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984;70(suppl I):208-12.
16. Dietl CA, Benoit CH, Gilbert CL, et al. Which is the graft of choice for the right coronary and posterior descending arteries? Circulation 1995;92(suppl II):92-7.
17. Manapat AE, Mc Crathy PM, Lytle BW, et al. Gastroepiploic and inferior epigastric arteries for coronary artery bypass. Circulation 1994;90(suppl II): 144-7.
18. Sarabu MR, McClung J, Fass A, Reed GE. Early postoperative spasm in the left internal mammary artery bypass grafts. Ann Thorac Surg 1987;44:199-200.
19. Jones EL, Lattouf OM, Weinstraub WS. Catastrophic consequences of internal mammary artery hypoperfusion. J Thorac Cardiovasc Surg 1989;98:902-7.
20. Suma H. Spasm of the right gastroepiploic artery. Ann Thorac Surg 1990;49:168-9.
21. Sakamoto T, Yamada T. Hemodynamic effects of dobutamine in patients following open heart surgery. Circulation 1977;55:525-33.
22. Myers ML, Li GH, Yaghi A, McCormack D. Human internal thoracic artery reactivity to dopaminergic agents. Circulation 1993;88(suppl 2):110-4.
23. Stanke F, Devillier P, Bréant D, et al. Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle. Br J Clin Pharmacol 1998;46:571-5.
24. He GW, Rosenfeldt FL, Buxton BF, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Circulation 1989;80(suppl I):141-50.
25. Pöch G, Holzmann S. Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves. J Pharmacol Methods 1980;4:179-88.
26. He GW, Yang CQ, Gately H, et al. Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries. Br J Clin Phannacol 1996;41:101-7.
27. Nicholson CD, Challiss RA, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase inhibitors. TIPS 1991;12:19-27.
28. Liu JJ, Doolan LA, Xie B, Chen JR, Buxton BF. Direct vasodilator effect of milrinone, an inotropic drug, on arterial coronary bypass grafts. J Thorac Cardiovasc Surg 1997;113:108-13.
29. O'Neil GS, Chester AH, Schyns CJ, Tadjkarimi S, Pepper JR, Yacoub MH. Vascular reactivity of human internal mammary and gastroepiploic arteries. Ann Thorac Surg 1991;52:1310-4.
30. Chardigny C, Jebara VA, Acar C, et al. Vasoreactivity of the radial artery. Circulation 1993;88(suppl II):115-27.
31. 2 levels during cardiopulmonary bypass. Circulation 1980;61:808-13.
32. Addonizio VP, Smith JB, Strauss JF, Colman RW, Edmunds LH. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenator. J Thorac Cardiovasc Surg 1980;79:91-6.
33. 2 during coronary revascularization. J Thorac Cardiovasc Surg 1987;93:120-6.
34. Ylikorkala O, Saarela E, Viinikka L. Increased prostacyclin and thromboxane production in man during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981;82:245-7.
35. Reves JG, Karp RB, Buttner EE, et al. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation 1982;66:49-54.
36. 1-adrenoceptor-mediated contraction in the human internal mammary artery. J Cardiovasc Phannacol 1993;21:256-63.
37. He GW, Yang CQ. Inhibition of vasoconstriction by phosphodiesterase III inhibitor milrinone in human conduit arteries used as coronary bypass grafts. J Cardiovasc Phannacol 1996;28:208-14.
38. Boldt J, Kling D, Dieterich HA, Marck P, Hempelmann G. The new phosphodiesterase inhibitor enoximone in patients following cardiac surgery: pharmacokinetics and influence on parameters of coagulation. Intens Care Med 1990;16:54-9.
39. Morita S, Sawai Y, Heeg J, Koike Y. Pharmacokinetics of enoximone after various intravenous administration to healthy volunteers. J Pharmacol Sci 1995;2:152-7.
40. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem Pharmacol 1986;35:787-800.
41. Thorin-Trescases N, Dimitri WR, Dominiczak AF, Hamilton CA, Reid JL. Vasorelaxant properties of isolated human internal mammary arteries and saphenous veins: comparative effects of milrinone and sodium nitroprusside. J Cardiovasc Pharmacol 1993;22: 673-80.
42. Haynes J, Robinson J, Saunders L, Taylor AE, Strada SJ. Role of cAMP-dependent protein kinase in cAMP-mediated vasodilation. Am J Physiol 1992;262:H511-6.
43. Caroll JD, Lang RM, Neumann AL, Borow KM, Rajfer SI. The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy. Circulation 1986;4:815-25.
44. Kates RE, Leier CV. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 1978;24:537-41.
45. Leier CV, Unverferth DV, Kates RE. The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med 1979;66:238-42.
46. Klem C, F DJ, Reilley TE, Flancbaum LJ. Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients. Crit Care Med 1994;22:1926-32.
47. Fujimoto S. Effects of pimobendan, its active metabolite UD-CG 212, and milrinone on isolated blood vessels. Eur J Pharmacol 1994;265:159-66.
48. Vincent JL, Leon M, Berre J, Melot C, Kahn RJ. Addition of enoximone to adrenergic agents in the management of severe heart failure. Crit Care Med 1992;20:1102-6.